Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA2PREVENT: Alpha 2 Agonists for Delirium Prevention After Heart Surgery
NCT05029050Phase 4Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dexmedetomidine, clonidine in delirium, No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity., sponsored by Oslo University Hospital. Started Jan 2022; status: recruiting.
02
Drugs
dexmedetomidineclonidine
03
Conditions
deliriumNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT05029050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029050.